Research
Hormonal
SGLT-2 inhibitors (SGLT-2is) reduce major adverse cardiovascular events and renal outcomes in patients with Type 2 Diabetes, with specific agents like empagliflozin and canagliflozin showing significant benefits.
If you have Type 2 Diabetes and heart or kidney issues, ask your doctor about SGLT-2 inhibitors like empagliflozin or canagliflozin. These pills help your body remove excess sugar through urine, which has been shown to significantly protect your heart and kidneys. They are often used alongside metformin.
StrongSupportsHIGH confidence
For all atherosclerotic CVD, SGLT-2i resulted in an 11% decrease in the 3p-MACE... Canagliflozin reduced CV death by 13% and empagliflozin reduced CV death by 38%... Canagliflozin reduced the primary renal-specific composite ESKD, renal or CV death by 34% over a median follow-up of 2.62 years.
Why this rating
Based on large CVOTs (EMPA-REG, CANVAS, DECLARE-TIMI 58, CREDENCE).
Source
Technological and Therapeutic Approaches to Type 2 Diabetes Management
Rekha Krishnan et al. · International Journal of Health Sciences and Research · 2023
DOI 10.52403/ijhsr.20230320
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (GLP-1RAs) significantly reduce major adverse cardiovascular events (MACE) and all-cause mortality in patients with type 2 diabetes, with specific agents like liraglutide and semaglutide demonstrating superior efficacy.Strong
- Tirzepatide, a dual GIP and GLP-1 receptor agonist, demonstrates superior glycemic control and weight loss compared to semaglutide and insulin degludec in patients with Type 2 Diabetes.Good
- Continuous Glucose Monitoring (CGM) and Flash Glucose Monitoring systems improve glycemic control and reduce hypoglycemia risk in patients with Type 2 Diabetes, particularly those on insulin therapy.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →